Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim Securities Healthcare Innovation ...

KRYS beat on both earnings and sales in the third quarter of 2024. Lead drug Vyjuvek's launch in the United States shows strong uptake.

"Witness a huge, painful cyst pop as Dr. Dustin Portela reveals the treatment process. Dr. Dustin Portela, 208skindoc, focuses on skin care education and solutions, offering expert tips, product ...

Krystal Biotech (KRYS) has received a new Buy rating, initiated by William Blair analyst, Sami Corwin. Sami Corwin has given his Buy rating due ...

Third Quarter 2024 Results Key Financial Results Revenue: US$83.8m (up by US$75.3m ...

November 4, 2024Krystal Biotech, Inc. beats earnings expectations. Reported EPS is $0.909, expectations were $0.9. Operator: Thank you for standing by and welcome to Krystal Biotech's Third Quarter ...

在炎炎夏日，戛纳电影节如约而至，星光熠熠的红毯上，一位东方美人的身影吸引了全世界的目光。她，就是韩国人气女星Krystal郑秀晶。今天，让我们跟随她的脚步，一起感受戛纳海边的夏天。

In July, Krystal franchisee WAC Enterprises opened its 92nd location in Arab, Alabama, a community with a population under ...

周一，花旗将Krystal生物科技(NASDAQ:KRYS)的目标股价从之前的$204.00上调至$206.00。尽管如此，花旗仍维持中性评级。这一调整是在评估Krystal生物科技的销售和管理层指引后做出的。 Krystal生物科技报告其基因疗法产品Vyjuvek的销售额为$83.8百万，与花旗预估的$82.3百万和市场共识的$83.4百万基本一致。然而，花旗注意到一些令人担忧的问题，特别是患者 ...

基因疗法公司Krystal Biotech Inc. (NASDAQ: KRYS)宣布2024年第三季度实现盈利，每股收益显著增加，其主打产品VYJUVEK的收入大幅增长。在2024年11月1日的业绩电话会议上，公司概述了其成功的商业策略，包括高度关注患者和医生体验，这推动了需求和报销审批。Krystal Biotech还讨论了其临床管线的进展，并提供了在欧洲和日本扩张计划的最新情况。 要点摘要 ...

Tamarac resident Krystal Patterson defeated incumbent Commissioner Elvin Villalobos for the city's District 3 commission seat ...

Thank you for standing by and welcome to Krystal Biotech's third-quarter earnings conference call. (Operator Instructions) As a reminder, today's conference is being recorded. I would now like to hand ...